ThinkEquity Downgrades Salix Pharma (SLXP) Following CRL for Relistor
Tweet Send to a Friend
ThinkEquity downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Hold.
This article: 56 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 56 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


